Previous 10 | Next 10 |
Amneal Pharmaceuticals Inc. Class A (AMRX) is expected to report $0.1 for Q3 2023
2023-11-06 11:32:09 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is $0.13 (-7.1% Y/Y) and the consensus Revenue Estimate is $604.53M (+10.8% Y/Y). Over the...
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
2023-10-23 16:23:28 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal to reorganize and simplify corporate structure Amneal gets approval for generic injectable on FDA's shortage list For further details ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...
2023-10-17 16:34:51 ET Amneal Pharmaceuticals ( NYSE: AMRX ) said that it plans to reorganize and simplify its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure. The biotech company said it intends to convert to a more traditional c...
- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
2023-09-24 07:37:29 ET Summary Amneal Pharmaceuticals exhibits strong Q2 performance with $599M in revenue and diversification in generics and biosimilars. However, its $2.59B long-term debt overshadows growth, raising concerns over liquidity and future financing options. Inve...
2023-09-06 18:16:56 ET More on Amneal Pharmaceuticals Seeking Alpha’s Quant Rating on Amneal Pharmaceuticals Historical earnings data for Amneal Pharmaceuticals Financial information for Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2023 Q2 - Res...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...